Compare AHCO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | OLMA |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2017 | 2020 |
| Metric | AHCO | OLMA |
|---|---|---|
| Price | $10.16 | $9.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $13.50 | ★ $44.89 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,244,857,000.00 | N/A |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.33 | $3.90 |
| 52 Week High | $13.43 | $36.26 |
| Indicator | AHCO | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 27.74 |
| Support Level | $9.87 | $7.79 |
| Resistance Level | $10.21 | $11.54 |
| Average True Range (ATR) | 0.31 | 0.78 |
| MACD | 0.07 | -0.15 |
| Stochastic Oscillator | 67.98 | 8.46 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.